Reng-na Yan

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND To investigate whether saxagliptin add-on therapy to continuous subcutaneous insulin infusion (CSII) further improve blood glycemic control than CSII therapy in patients with newly diagnosed type 2 diabetes (T2D). METHODS This was a single-center, randomized, control, open-labeled trial. Newly diagnosed T2D patients were recruited between(More)
  • 1